We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

25 hedge funds and large institutions have $6.85M invested in Inhibikase Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

19% more funds holding

Funds holding: 21 → 25 (+4)

0.37% more ownership

Funds ownership: 2.72% → 3.09% (+0.37%)

12% less capital invested

Capital invested by funds: $7.78M → $6.85M (-$934K)

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$370K
2
ACM
ACT Capital Management
Pennsylvania
+$122K
3
State Street
State Street
Massachusetts
+$105K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$98.1K
5
Northern Trust
Northern Trust
Illinois
+$24.2K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$192K
2
M
Murchinson
Ontario, Canada
-$184K
3
Goldman Sachs
Goldman Sachs
New York
-$53K
4
WAM
Warberg Asset Management
Illinois
-$24.9K
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
ACT Capital Management
Pennsylvania
$1.58M +$122K +11,084 +7%
KC
2
Kepos Capital
New York
$1.03M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$704K – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$637K – – –
SM
5
Sabby Management
Florida
$625K – – –
AC
6
Antara Capital
New York
$445K – – –
LCM
7
Lynwood Capital Management
Ontario, Canada
$375K +$469K +42,500 New
M
8
Murchinson
Ontario, Canada
$327K -$184K -16,666 -31%
Renaissance Technologies
9
Renaissance Technologies
New York
$296K +$370K +33,533 New
RPCONE
10
Retirement Planning Company of New England
Rhode Island
$216K +$271K +24,555 New
ZCA
11
Zeke Capital Advisors
Pennsylvania
$138K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$116K +$98.1K +8,882 +206%
State Street
13
State Street
Massachusetts
$84K +$105K +9,483 New
BlackRock
14
BlackRock
New York
$79K +$6.07K +550 +7%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$58K – – –
Northern Trust
16
Northern Trust
Illinois
$42K +$24.2K +2,193 +84%
SC
17
Shay Capital
New York
$29K – – –
WAM
18
Warberg Asset Management
Illinois
$18K -$24.9K -2,251 -52%
KJHP
19
K.J. Harrison & Partners
Ontario, Canada
$17K +$20.8K +1,883 New
Two Sigma Investments
20
Two Sigma Investments
New York
$17K +$21.2K +1,917 New
TRCT
21
Tower Research Capital (TRC)
New York
$10K +$1.83K +166 +18%
UBS Group
22
UBS Group
Switzerland
$3K -$12.5K -1,132 -79%
MAM
23
Mystic Asset Management
Rhode Island
$3K +$4.18K +379 New
Millennium Management
24
Millennium Management
New York
– -$192K -16,880 Closed
Goldman Sachs
25
Goldman Sachs
New York
– -$53K -4,649 Closed
1
2

IKT Hedge Fund Activity: Q4 2021 in Review

25 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2021, worth a combined $6.85M — down 12% from $7.78M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new IKT positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $370K. The largest seller was Millennium Management, exiting entirely with an estimated $192K sold.

  • 25 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2021, up from 21 in Q3 2021.
  • Funds reported $6.85M of Inhibikase Therapeutics stock for Q4 2021, down 12% quarter-over-quarter.
  • 8 funds opened new Inhibikase Therapeutics positions in Q4 2021 and 4 closed out, a net change of +4 holders.
  • The largest Inhibikase Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $370K added.
  • The largest Inhibikase Therapeutics seller in Q4 2021 was Millennium Management, an estimated $192K sold.

Based on aggregated 13F filings for Q4 2021.